Neuren Doses First Patient in Landmark Phase 3 Trial for Phelan-McDermid Syndrome

An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.

Neuren Pharmaceuticals has dosed the first patient in its Koala Phase 3 clinical trial of NNZ-2591 for Phelan-McDermid syndrome, marking the first-ever Phase 3 study in this rare neurodevelopmental disorder, which currently has no approved treatments. The randomized, double-blind, placebo-controlled trial plans to enroll about 160 children aged 3 to 12 across a growing network of U.S. sites, supported by Fast Track, Rare Pediatric Disease and Orphan Drug designations from the FDA; early referral and waitlist numbers suggest strong interest from the patient community, while Neuren’s sponsorship of the 2026 Phelan-McDermid Syndrome Foundation Family Conference underscores its engagement with stakeholders and signals building momentum around NNZ-2591’s late-stage development.

The most recent analyst rating on (AU:NEU) stock is a Hold with a A$15.50 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals is an Australian biopharmaceutical company focused on developing novel drug therapies for serious neurological and neurodevelopmental disorders that emerge in early childhood and currently have no or limited treatment options. Its lead commercial product, trofinetide, is marketed in the United States as DAYBUE and DAYBUE STIX for Rett syndrome under an exclusive worldwide licence to Acadia Pharmaceuticals, while its second drug candidate, NNZ-2591, is in clinical development for multiple rare neurodevelopmental syndromes including Phelan-McDermid, Pitt Hopkins and Angelman syndromes, all of which hold orphan drug designations in the US and EU.

Average Trading Volume: 356,306

Technical Sentiment Signal: Sell

Current Market Cap: A$1.85B

For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.